medigraphic.com
ISSN 1561-3011 (Electronic)

2022, Number 1

<< Back Next >>

Rev Cubana Invest Bioméd 2022; 41 (1)

Bile acids and the lung: expectations to take into account in the COVID-19

Piñol JFN, Capó PV, Ruiz TJF, Montero GT, Borrajero MI, Domínguez ÁC, Hurtado MAJ, Gra OB, Mönkemüller K

Language: Spanish
References: 42
Page: 1-15
PDF size: 268.39 Kb.


ABSTRACT

Bile acids, signaling molecules, maintain immune tolerance, their lack of control amplifies the inflammatory response from the hepato-intestinal system to other organs such as the lung. Liver dysfunction affects anatomical and functional structures of various organs and increases the risk of mortality due to cytotoxicity of bile acids. To describe the possible biomolecular evidence that could support bile acids pro-inflammatory agents of respiratory complications in Covid-19, a systematic and critical review of what has been published between 1946-2021 is presented, on the toxic actions of bile acids under conditions supraphysiological on the alveolar tissue. This could constitute the theoretical foundation that associates hepato-intestinal dysfunction-bile acids-alveolar damage in COVID-19, and would allow the hypothesis of considering the bile acids constituent of an axis that transversalizes the COVID-19 process, when participating actively in its clinical stages, and therefore being metabolomic agents that amplify or perpetuate the inflammatory response created by SARS-CoV2. Clinical studies are recommended for confirmation in the progress of acute respiratory distress syndrome.


REFERENCES

  1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors formortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet. [Internet]. 2020. [Consultado 2021 ene 22];395(10229):1054e62. Disponible en:https://doi.org/10.1016/S0140-6736(20)30566-3.

  2. Carsana L, Sonzogni A, Nasr A, Rossi R, Pellegrinelli A, Zerbi P, et al. Pulmonary postmortemfindings in a large series of COVID-19 cases from Northern Italy. Med Rxiv.[Internet]. 2020. [Consultado 2021 ene 22];04.19.20054262. Disponible en:https://doi.org/10.1101/2020.04.19.20054262.

  3. Fiorucci S, Biagioli M, Zampella A, Distrutti E. Bile acids activated receptors regulateinnate immunity. Front Immunol. [Internet].2018. [Consultado 2021 ene 22];9:1853.Disponible en: https://doi.org/10.3389/fimmu.2018.01853.

  4. Aldhahrani A, Verdon B, Ward C, Pearson J. Effects of bile acids on human airwayepithelial cells: implications for aerodigestive diseases. ERJ Open Res. [Internet]. 2017.[Consultado 2021 ene 22];3:00107-2016. Disponible en:https://doi.org/10.1183/23120541.00107-2016

  5. Wu JN, Chen JR, Chen JL. Role of Farnesoid X Receptor in the Pathogenesis ofRespiratory Diseases. Can Respir J. [Internet]. 2020 [Consultado 2021 ene22];2020:9137251. Disponible en: https://doi.org/10.1155/2020/9137251.

  6. Lee J, Im JP, Han K, Park S, Soh H, Choi K, et al. Risk of inflammatory bowel diseasein patients with chronic obstructive pulmonary disease: a nationwide, population-basedstudy. World J Gastroenterol. [Internet]. 2019. [Consultado 2021 ene 22];25:6354–64.Disponible en: https://doi.org/10.3748/wjg.v25.i42.6354.

  7. Krones E, Wagner M, Eller K, Rosenkranz AR, Trauner M, Fickert P. Bile Acid-InducedCholemic Nephropathy. Dig Dis. [Internet]. 2015. [Consultado 2021 ene 22];33:367–75.Disponible en: https://doi.org/10.1159/000371689.

  8. Desai M, Mathur B, Eblimit Z, Vasquez H, Taegtmeyer H, Karpen S, et al. Bile acidexcess induces cardiomyopathy and metabolic dysfunctions in the heart. Hepatology.[Internet]. 2017. [Consultado 2021 ene 22];65(1):189–201. Disponible en:https://doi.org/10.1002/hep.28890.

  9. Zhao C, Wang X, Cong Y, Deng Y, Xu Y, et al. Effects of Bile Acids and the Bile AcidReceptor FXR Agonist on the Respiratory Rhythm in the In Vitro Brainstem Medulla Slice of Neonatal Sprague-Dawley Rats. PLoS ONE. [Internet]. 2014. [Consultado 2021 ene22];9(11):e112212. Disponible en: http://doi.org/:10.1371/journal.pone.0112212.

  10. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al.Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med.[Internet]. 2010. [Consultado 2021 ene 22];363: 1128–38. Disponible en:http://doi.org/:10.1056/NEJMoa0909883.

  11. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. [Internet].2001 [Consultado 2021 ene 22];344: 665–71. Disponible en:http://doi.org/:10.1056/NEJM200103013440908.

  12. Guillot L, Nathan N, Tabary O, Thouvenin G, Le Rouzic P, Corvol H, Amselem S,Clement A. Alveolar epithelial cells: master regulators of lung homeostasis. Int J BiochemCell Biol. [Internet]. 2013 [Consultado 2021 ene 22];45(11):2568-73. Disponible en:https://doi.org/10.1016/j.biocel.2013.08.009.

  13. Lugones Y, Blanco O, López-Rodriguez E, Echaide M, Cruz A, Pérez-Gil J. Inhibitionand counterinhibition of Surfacen, a clinical lung surfactant of natural origin. PLoS ONE.[Internet]. 2018. [Consultado 2021 ene 22];13(9):e0204050. Disponible en:https://doi.org/10.1371/journal.pone.0204050.

  14. Sardesai S, Biniwale M, Wertheimer F, Garingo A, Ramanathan R. Evolution ofsurfactant therapy for respiratory distress syndrome: past, present, and future. Pediatr Res.[Internet]. 2017. [Consultado 2021 ene 22];81(1-2):240-8. Disponible en:https://doi.org/10.1038/pr.2016.203.

  15. Sorensen GL. Surfactant protein D in respiratory and Non-respiratory diseases. FrontMed. [Internet]. 2018. [Consultado 2021 ene 22];5:18. Disponible en:https://doi.org/10.3389/fmed.2018.00018

  16. Wang F, Zhao C, Tian YH, Yin YR. Effect of high blood levels of bile acid onrespiratory functions of New Zealand rabbits. J South Med Univ. [Internet]. 2013.[Consultado 2021 ene 22];33:1181–84. Disponible en:https://pubmed.ncbi.nlm.nih.gov/23996762/.

  17. Malhi H, Camilleri M. Modulating bile acid pathways and TGR5 receptors for treatingliver and GI diseases. Curr Opin Pharmacol. [Internet]. 2017. [Consultado 2021 ene 22];37:80–6. Disponible en: https://doi.org/10.1016/j.coph.2017.09.008.

  18. Nakada EM, Bhakta NR, Korwin-Mihavics BR, Kumar A, Chamberlain N, Bruno SR,et al. Conjugated bile acids attenuate allergen-induced airway inflammation andhyperresponsiveness by inhibiting UPR transducers. JCI Insight. [Internet]. 2019. [Consultado 2021 ene 22];4(9):e98101. Disponible en:https://doi.org/10.1172/jci.insight.98101.

  19. Chen B, You WJ, Xue S, Qin H, Zhao XJ, Zhang M, Liu XQ, et al. Overexpression offarnesoid X receptor in small airways contributes to epithelial to mesenchymal transitionand COX-2 expression in chronic obstructive pulmonary disease. J Thorac Dis. [Internet].

  20. 2016. [Consultado 2021 ene 22];8(11):3063-3074. Disponible en:https://doi.org/10.21037/jtd.2016.11.08.20. Wu Y-C, Hsu P-K, Su K-C, Liu L-Y, Tsai C-C Tsai, S-H, et al. Bile acid aspiration insuspected ventilator-associated pneumonia. Chest. [Internet]. 2009. [Consultado 2021 ene22];136: 118–24. Disponible en: https://doi.org/10.1378/chest.08-2668.

  21. Autilio C, Shankar-Aguilera S, Minucci A, Touqui L, De Luca D. Effect of cooling onlung secretory phospholipase A2 activity in vitro, ex vivo, and in vivo. Am J Physiol LungCell Mol Physiol. [Internet]. 2019. [Consultado 2021 ene 22];316: L498–L505. Disponibleen: https://doi.org/10.1152/ajplung.00201.2018.

  22. Su KC, Wu YC, Chen CS, Hung MH, Hsiao YH, Tseng CM, et al. Bile acids increasealveolar epithelial permeability via mitogen-activated protein kinase, cytosolicphospholipase A2, cyclooxygenase-2, prostaglandin E2 and junctional proteins.Respirology. [Internet]. 2013. [Consultado 2021 ene 22];18:848-56. Disponible en:https://doi.org/10.1111/resp.12086.

  23. Perng DW, Wu YC, Tsai CC, Su KC, Liu LY, Hsu WH, et al. Bile acids induce CCN2production through p38 MAP kinase activation in human bronchial epithelial cells: a factorcontributing to airway fibrosis. Respirology. [Internet]. 2008. [Consultado 2021 ene22];13:983-9. Disponible en: https://doi.org/10.1111/j.1440-1843.2008.01402.x.

  24. Oyarzún GM. Función respiratoria en la senectud. Rev Méd Chile. [Internet]. 2009.[Consultado 2021 ene 22];137: 411-8. Disponible en: https://dx.doi.org/10.4067/S0034-98872009000300014.

  25. Zecca E, Costa S, Lauriola V, Vento G, Papacci P, Romagnoli C. Bile acid pneumonia:a "new" form of neonatal respiratory distress syndrome?. Pediatrics. [Internet]. 2004.[Consultado 2021 ene 22];58:44-7;114(1):269-72. Disponible en:https://doi.org/10.1542/peds.114.1.269.

  26. Kaneko T, Satot Katsuyatt, et al. Surfactant therapy for pulmonary edema due tointratracheally infected bile acid. Crit Care Med. [Internet]. 1990. [Consultado 2021 ene22];18:77-83. Disponible en: https://doi.org/10.1097/00003246-199001000-00017

  27. Zhang D, Li S, Wang N, Zhang Z, Feng Y, et al. The cross-talk between gut microbiotaand lungs in common lung diseases. Front Microbiol. [Internet] 2020. [Consultado 2021 ene22]; 11, 301. Disponible en: https://doi.org/10.3389/fmicb.2020. 00301.

  28. Dumas A, Bernard L, Poquet Y, Villarino GL, Neyrolles O, et al. The role of the lungmicrobiota and the gut-lung axis in respiratory infectious diseases. Cell Microbiol. [Internet]2018 [Consultado 2021 ene 22];20(12):e12966. Disponible en:https://doi.org/10.1111/cmi.12966.

  29. Beaudoin , J.J., Bezençon, J., Sjöstedt, N., Fallon, J.K., Brouwer, K. L.R. Role ofOrganic Solute Transporter Alpha/Beta in Hepatotoxic Bile Acid Transport and DrugInteractions. Toxicoll Sc. [Internet] 2020 [Consultado 2021 ene 22];176(1),34–45.Disponible en: https://doi.org/10.1093/toxsci/kfaa052

  30. Huang D, Xiong M, Xu X , Wu X , Xu J , Cai X, Lu L , ZHou H. Bile acids elevated byhigh-fat feeding induce endoplasmic reticulum stress in intestinal stem cells and contributeto mucosal barrier damage. Biochem Biophys Res Commun. [Internet] 2020 [Consultado2021 ene 22];529(2):289-95. Disponible en: https://doi.org/10.1016/j.bbrc.2020.05.226.

  31. Vítek L. Bile acid malabsorption in inflammatory bowel disease. Inflamm Bowel Dis.[Internet] 2015 [Consultado 2021 ene 22];21:476–483. Disponible en:https://doi.org/10.1097/MIB.0000000000000193.

  32. Su KC, Wu YC, Chen CS, Hung MH, Hsiao YH, Tseng CM, Chang SC, Lee YC, PerngDW. Bile acids increase alveolar epithelial permeability via mitogen-activated proteinkinase, cytosolic phospholipase A2, cyclooxygenase-2, prostaglandin E2 and junctionalproteins. Respirology. [Internet] 2013 [Consultado 2021 ene 22];18(5):848-56. Disponibleen: https://doi.org/doi: 10.1111/resp.12086.

  33. Aktas B, Aslim B. Gut-lung axis and dysbiosis in COVID-19. Turk J Biol. [Internet].2020. [Consultado 2021 ene 22];44:265-72. Disponible en: https://doi.org/10.3906/biy-2005-102 .

  34. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosisof COVID-19. J Pharm Anal. [Internet]. 2020. [Consultado 2021 ene 22];10(2): 02-8.Disponible en: https://doi.org/10.1016/j.jpha.2020.03.001.

  35. Musa S. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now? Arab J Gastroenterol. [Internet]. 2020 [Consultado 2021ene 22];21(1):3-8. Disponible en: https://doi.org/10.1016/j.ajg.2020.03.002.

  36. Adachi T, Chong JM, Nakajima N, Sano M, Yamazaki J, Miyamoto I, et al.Clinicopathologic and Immunohistochemical Findings from Autopsy of Patient with COVID-19, Japan. Emerg Infect Dis. [Internet]. 2020 [Consultado 2021 ene22];26(9):2157–61. Disponible en: https://doi.org/10.3201/eid2609.201353.

  37. Capó de Paz V, Borrajero Martínez I, Montero González T, Hurtado de Mendoza AmatJ, de Armas Rodríguez Y, Domínguez Alvarez C. Hallazgos de autopsias de 50 fallecidoscon SARS-CoV-2 en Cuba entre abril y septiembre de 2020. [Internet]. 2021 [Consultado2021 ene 22];11(2): [aprox. 0 p.]. Disponible en:http://revistaccuba.sld.cu/index.php/revacc/article/view/994

  38. Yang D, Xing Y, Song X, Qian Y. The impact of lung microbiota dysbiosis oninflammation. Immunology. [Internet]. 2020. [Consultado 2021 ene 22];159(2):156-66.Disponible en: https://doi.org/10.1111/imm.13139.

  39. Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory viral infection-inducedmicrobiome alterations and secondary bacterial pneumonia. Front Immunol. [Internet].2018. [Consultado 2021 ene 22];9:1-15. Disponible en:https://doi.org/10.3389/fimmu.2018.02640

  40. Abdulrab S, Al-Maweri S, Halboub E. Ursodeoxycholic acid as a candidate therapeuticto alleviate and/or prevent COVID-19-associated cytokine storm. Med Hypotheses.[Internet]. 2020 [Consultado 2021 ene 22];143:109897. Disponible en:https://doi.org/10.1016/j.mehy.2020.109897.

  41. Subramanian S, Iles T, Ikramuddin S, Steer CJ. Merit of an Ursodeoxycholic AcidClinical Trial in COVID-19 Patients. Vaccines [Internet]. 2020 [Consultado 2021 ene22];8(2):320. Disponible en: https://doi.org/10.3390/vaccines8020320.

  42. Brevini T, Maes M, Webb GJ, Gelson WTH, Forrest S, Mlcochova P, et al. FXRinhibition reduces ACE2 expression, SARS-CoV-2 infection and may improve COVID-19outcome. BioRxiv. [Internet] 2021[Consultado en Ags 2021]; preprint: Disponible en:https://doi.org/10.1101/2021.06.06.446781.




2020     |     www.medigraphic.com